Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Hisamitsu Pharmaceutical Co ( (JP:4530) ) has issued an announcement.
Taiyo Kosan Co., Inc. has successfully completed its tender offer for Hisamitsu Pharmaceutical’s common stock, share acquisition rights and American Depositary Shares, which ran from January 7 to February 19, 2026. A total of 41,803,599 shares were tendered, surpassing the minimum threshold of 41,119,400 shares required for the bid to succeed.
Following settlement of the tender offer scheduled for February 27, 2026, Taiyo Kosan’s ownership will exceed 50% of Hisamitsu’s voting rights. This shift will make Taiyo Kosan the new parent company and largest major shareholder, marking a significant change in control that will likely influence Hisamitsu’s future governance and strategic direction.
The most recent analyst rating on (JP:4530) stock is a Buy with a Yen7130.00 price target. To see the full list of analyst forecasts on Hisamitsu Pharmaceutical Co stock, see the JP:4530 Stock Forecast page.
More about Hisamitsu Pharmaceutical Co
Hisamitsu Pharmaceutical Co., Inc. is a Japanese drugmaker best known for producing pharmaceuticals, including transdermal patches and other healthcare products. The company operates in the broader pharmaceutical and healthcare sector, serving both domestic and international markets through listed common shares and American Depositary Shares.
Average Trading Volume: 364,271
Technical Sentiment Signal: Buy
Current Market Cap: Yen455.9B
Find detailed analytics on 4530 stock on TipRanks’ Stock Analysis page.